Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Petrelintide

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Roche · Phase 2 · Completed · Enrollment 221

NCT06926842

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Treatment A: Petrelintide Dose 1n/rn/rn/rn/r
Treatment B: Petrelintide Placebo Dose 1n/rn/rn/rn/r
Treatment C: Petrelintide Dose 2n/rn/rn/rn/r
Treatment D: Petrelintide Placebo Dose 2n/rn/rn/rn/r
Treatment E: Petrelintide Dose 3n/rn/rn/rn/r
Treatment F: Petrelintide Placebo Dose 3n/rn/rn/rn/r

Not shown

  • Treatment A: Petrelintide Dose 1: endpoint not reported
  • Treatment B: Petrelintide Placebo Dose 1: endpoint not reported
  • Treatment C: Petrelintide Dose 2: endpoint not reported
  • Treatment D: Petrelintide Placebo Dose 2: endpoint not reported
  • Treatment E: Petrelintide Dose 3: endpoint not reported
  • Treatment F: Petrelintide Placebo Dose 3: endpoint not reported